JPRN-jRCT2080222115未知3 期
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 920
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Non-small cell lung cancer (NSCLC) - squamous cell
- •Stage IV or recurrent NSCLC
- •Eastern Cooperative Oncology Group (ECOG) of 0 or 1
排除标准
- •Brain Metastases
- •Autoimmune diseases
研究者
相似试验
进行中（未招募）
1 期
Scientific Study to compare the efficiency of Ipilimumab combined with Paclitaxel and Carboplatin with Paclitaxel and carboplatin alone in the treatment of Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC).Stage IV/Recurrent Non-Small Cell Lung CancerMedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017396-19-DEBristol-Myers Squibb International Corporation920
进行中（未招募）
1 期
Phase 3 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneExtensive Stage Disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 17.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000850-48-NLBristol-Myers Squibb International Corporation1,100
进行中（未招募）
1 期
Scientific Study to compare the efficiency of Ipilimumab combined with Paclitaxel and Carboplatin with Paclitaxel and carboplatin alone in the treatment of Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC).Stage IV/Recurrent Non-Small Cell Lung CancerMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017396-19-ATBristol-Myers Squibb International Corporation920
进行中（未招募）
1 期
Phase 3 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneExtensive Stage Disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 14.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000850-48-IEBristol-Myers Squibb International Corporation1,100
进行中（未招募）
1 期
Scientific Study to compare the efficiency of Ipilimumab combined with Paclitaxel and Carboplatin with Paclitaxel and carboplatin alone in the treatment of Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC).Stage IV/Recurrent Non-Small Cell Lung CancerMedDRA version: 18.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017396-19-CZBristol-Myers Squibb International Corporation920